New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 14, 2014
08:15 EDTBCR, JNJ, COV, BSX, ZMH, MDTRepeal of medical device tax pushed by Republicans, Bloomberg says
Republicans are trying to include the repeal of a medical device excise tax that has been opposed by companies such as Medtronic (MDT) and Boston Scientific (BSX) in a package of tax breaks moving through the Senate, reported Bloomberg. Other publicly traded medical device makers include Johnson & Johnson (JNJ), Zimmer (ZMH), Covidien (COV), and C.R. Bard (BCR). Reference Link
News For MDT;BSX;JNJ;ZMH;COV;BCR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
May 20, 2015
07:16 EDTMDTLeerink to hold a booth tour at EuroPCR
Subscribe for More Information
06:17 EDTJNJAchillion downgraded to Neutral from Buy at UBS
Subscribe for More Information
05:31 EDTBSXNew study evaluating Boston Scientific Lotus Valve System shows low PVL rates
Subscribe for More Information
May 19, 2015
16:10 EDTJNJAchillion enters into collaboration for HCV with Janssen
Achillion (ACHN) announced that it has entered into a worldwide license and collaboration arrangement with Janssen Pharmaceuticals, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ), to develop and commercialize one or more of Achillion's lead hepatitis C virus, or HCV, assets which include ACH-3102, ACH-3422, and sovaprevir. Under the terms of the agreement, Achillion will grant Janssen an exclusive, worldwide license to develop and, upon regulatory approval, commercialize HCV products and regimens containing one or more of Achillion's HCV assets. Achillion is eligible to receive a number of payments based upon achievement of specified development, regulatory and sales milestones. Achillion is also eligible to receive tiered royalty percentages between mid-teens and low-twenties based upon future worldwide sales. Janssen will be responsible for all of the development costs within the collaboration and all subsequent costs related to commercialization of the HCV assets. A key objective of the collaboration will be to develop a short-duration, highly effective, pan-genotypic, oral regimen for the treatment of HCV. An initial regimen that will be explored will feature Achillion's ACH-3102, a second-generation NS5A inhibitor currently in Phase 2 clinical studies that has been granted Fast Track designation by the U.S. Food and Drug Administration, in combination with an NS3/4A HCV protease inhibitor plus an NS5B HCV polymerase inhibitor from the collaboration. Additionally, in an equity transaction separate to the exclusive license and collaboration arrangement, Johnson & Johnson Innovation JJDC, Inc. will invest $225M in Achillion and, in return, receive approximately 18.4M newly issued, unregistered shares of Achillion at a price of $12.25 per share. The transactions, including the equity sale, are subject to customary closing conditions, including termination or expiration of any applicable waiting periods under the Hart-Scott-Rodino Act. Transitional clinical development and technology transfer activities under the collaboration are expected to take place over the next several months.
08:40 EDTMDTMedtronic sees FY15 revenue $20.3B, may not compare to consensus $28.15B
Subscribe for More Information
08:40 EDTMDTMedtronic sees Q4 adjusted EPS at upper half of $1.08-1.13, consensus $1.10
Subscribe for More Information
07:54 EDTBSXBoston Scientific reports positive data from EVOLVE trial
Subscribe for More Information
May 18, 2015
16:51 EDTZMHBIOLASE CEO Jeffrey Nugent to step down, Harold Flynn appointed CEO
BIOLASE (BIOL) announced that Harold Flynn Jr. will become president and CEO, effective July 13. The current president and CEO Jeffrey Nugent will step down at that time. Since 2007, Flynn has been president of Zimmer Dental, a manufacturer and provider of medical devices for the dental market. Zimmer Dental is a division of Zimmer Holdings (ZMH).
09:27 EDTMDTMedtronic announces study results showing CRT system optimizes treatment
Subscribe for More Information
May 15, 2015
13:33 EDTMDTMedtronic: TYRX antibacterial envelope reduces cardiac device infection rates
Subscribe for More Information
10:29 EDTBSX, BCRAmerican Urological Association to hold an annual meeting
Subscribe for More Information
09:31 EDTBSXAmerican Thoracic Society to hold a conference
ATS 2015 Conference is being held in Denver on May 15-20.
08:12 EDTMDTMedtronic Micra TPS meets initial safety, performance measures
Subscribe for More Information
07:35 EDTJNJMedivation price target raised to $148 from $128 at Leerink
Subscribe for More Information
May 14, 2015
14:54 EDTJNJJohnson & Johnson unit reports results of VENTURE-AF trial
Subscribe for More Information
13:55 EDTZMHZimmer initiated with an Outperform at Northland
Subscribe for More Information
13:34 EDTMDTMedtronic: Micra transcatheter pacemaker meets initial safety measures in study
Subscribe for More Information
13:31 EDTMDTMedtronic says Evera MRI ICD study meets safety, efficacy endpoints
Subscribe for More Information
09:41 EDTJNJ, MDT, BSXLeerink medical devices analyst holds a cardiology luncheon meeting
Subscribe for More Information
08:45 EDTZMHZimmer has a conference call hosted by JPMorgan
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use